Retatrutide is hitting 22-24% weight loss in clinical trials. Tirzepatide is reaching 18-22%. Semaglutide caps out around 14-20%. If you weigh 100kg, that's the difference between dropping to 76kg (retatrutide) or 86kg (semaglutide). Same time frame. Different drug.
A 2026 systematic review analyzed 26 randomized controlled trials with 15,491 people (BMI 30-40, no diabetes) and found something interesting: adding more receptor targets makes a huge difference. Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Retatrutide hits three (GLP-1 + GIP + glucagon). More targets = more weight loss.
The head-to-head data from 2026
Here's what the latest meta-analysis found when comparing all three drugs over 16-104 weeks:
| Drug | Mechanism | Max Weight Loss | FDA Status | |------|-----------|-----------------|------------| | Semaglutide (2.4 mg weekly) | GLP-1 agonist | 14-20% (95% CI 11-17%) | Approved | | Tirzepatide (15 mg weekly) | GLP-1/GIP dual agonist | 18-22% (95% CI 16-19%) | Approved | | Retatrutide (12 mg weekly) | GLP-1/GIP/glucagon triple agonist | 22-24% (95% CI 19-25%) | Investigational |
All three are weekly subcutaneous injections. All three target the same core pathway (GLP-1), but retatrutide and tirzepatide add extra mechanisms on top.
Why tirzepatide beats semaglutide
A 2026 head-to-head meta-analysis looked at 12 studies comparing tirzepatide and semaglutide directly. Tirzepatide won by a significant margin:
- 4.61% greater percentage weight loss (95% CI -6.03 to -3.20)
- 4.76 kg more absolute weight loss
- Higher odds of hitting ≥5%, ≥10%, ≥15%, and ≥20% weight loss thresholds (odds ratios ranging from 1.52 to 2.82)
The GIP receptor seems to matter. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that affects insulin secretion, fat metabolism, and satiety. When you activate both GLP-1 and GIP together, you get better results than GLP-1 alone.
What makes retatrutide different
Retatrutide adds a third target: the glucagon receptor. Glucagon normally raises blood sugar, but in the context of a triple agonist, it seems to increase energy expenditure and fat burning without causing hyperglycemia (high blood sugar).
Early trials (up to 48 weeks) show retatrutide hitting 24% weight loss on higher doses. That's slightly better than tirzepatide's 22% at max dose. The confidence intervals overlap, so we can't say for sure that retatrutide is definitively better. but the trend is there.
Here's the practical translation: if you weigh 100kg and take retatrutide for a year, you'd expect to drop to around 76-78kg. On tirzepatide, you'd hit 78-82kg. On semaglutide, 80-86kg. All of this assumes you're on the highest dose and tolerate it well.
What happened in the SURMOUNT trials
The SURMOUNT-1 trial tested tirzepatide in people without diabetes. At the 15 mg dose, participants lost an average of 22.5% of their body weight over 72 weeks. That's 22.5kg for someone starting at 100kg.
No weight loss drug has ever hit those numbers before. Not even close. Phentermine, orlistat, naltrexone/bupropion. they all max out around 5-10% weight loss. GLP-1 agonists changed the game.
Retatrutide trials are still ongoing, but early Phase 2 data suggests it could edge out tirzepatide by another 2-4%. Eli Lilly (the company behind both tirzepatide and retatrutide) is betting big on the triple agonist.
The side effects everyone talks about
All three drugs cause gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation. it's the most common complaint. About 10% of people discontinue because they can't tolerate it.
The good news: side effects tend to peak during dose escalation and get better over time. Starting low and ramping up slowly helps. Most people who stick with it adapt within a few weeks.
There's no clear winner for tolerability. Tirzepatide and retatrutide might cause slightly more GI issues because they hit more receptors, but the data isn't consistent across trials. Some people tolerate semaglutide fine and hate tirzepatide. Others have the opposite experience.
What we still don't know
Retatrutide isn't FDA-approved yet. It's still in Phase 3 trials. You can't get a prescription for it unless you're in a clinical trial. Tirzepatide and semaglutide are both approved and available now.
We also don't have long-term data beyond 104 weeks for any of these drugs. What happens at year 3? Year 5? Do people maintain the weight loss, or does it creep back? The trials haven't run long enough to answer that yet.
Also, there's no direct head-to-head trial comparing all three drugs in the same study. The comparisons come from meta-analyses, which pool data from different trials. That introduces some uncertainty. A proper three-way RCT would settle this once and for all, but it probably won't happen. the drugs are made by competing companies.
Who should consider which drug
If you're choosing between these drugs right now, here's what the data suggests:
Semaglutide (Wegovy, Ozempic):
- Proven track record, widely available
- 14-20% weight loss is still excellent
- Lower cost than tirzepatide in some markets
- Good option if you want something established
Tirzepatide (Mounjaro, Zepbound):
- Best available option right now
- 18-22% weight loss, better than semaglutide
- Approved for diabetes and weight loss
- Slightly higher cost, but better results
Retatrutide:
- Not available yet (still in trials)
- Highest weight loss (22-24%) in early data
- If you're willing to wait, this could be the best option once approved
- Eli Lilly expects FDA review in late 2026 or early 2027
If you need something now, tirzepatide is the strongest choice. If you can wait, retatrutide might be worth it.
Key Takeaways
- Retatrutide (triple agonist) hits 22-24% weight loss, tirzepatide (dual agonist) hits 18-22%, semaglutide (single agonist) hits 14-20%
- More receptor targets = better results, but also possibly more side effects
- Tirzepatide beats semaglutide by 4.61% in head-to-head meta-analysis
- All three cause GI side effects in most people; about 10% discontinue
- Retatrutide isn't FDA-approved yet. still in Phase 3 trials
- If you need something now, tirzepatide is the best option available
This is educational content, not medical advice. Talk to your doctor before starting any protocol.